Epidiolex Phase III trial safety and efficacy data with/without clobazam

Epidiolex Phase III trial safety and efficacy data with/without clobazam The passage provides detailed clinical trial results for a pharmaceutical product but contains no references to high‑profile individuals, government agencies, financial misconduct, or controversial political actions. It offers no actionable investigative leads beyond standard medical data. Key insights: Adverse event rates were higher in Epidiolex arms than placebo but mostly mild/moderate.; Elevations in liver enzymes occurred, especially in patients also on valproic acid.; Efficacy appears modestly higher when Epidiolex is combined with clobazam.